Deals
Sucampo Pharmaceuticals Weighs Sale After Receiving Takeover Interest
- U.S. biopharmaceutical company attracting other drugmakers
- Shares surge as much as 18 percent; no final decision made
Photographer: Tomohiro Ohsumi/Bloomberg
This article is for subscribers only.
Sucampo Pharmaceuticals Inc., a U.S. biopharmaceutical company with a focus on gastroenterology, is reviewing options including a sale of the business after receiving takeover interest, according to people familiar with the matter.
The company, which hasn’t made a decision, may still decide against a sale and instead pursue growth through acquisitions, said the people, who asked not to be identified because the deliberations are private. The company could be attractive for large drugmakers with an interest in gastroenterology, the people said.